This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Avgeropoulos, N. G. Articles by Batchelor, T. T. Search for Related Content PubMed PubMed Citation Articles by Avgeropoulos, N. G. Articles by Batchelor, T. T.

New Treatment Strategies for Malignant Gliomas

Brain Tumor Center, Massachusetts General Hospital, Boston, Massachusetts, USA

Correspondence: Tracy T. Batchelor, M.D., M.P.H., Massachusetts General Hospital, Brain Tumor Center, Cox 03-15, 100 Blossom Street, Boston, Massachusetts 02114, USA. Telephone: 617-724-8770; Fax: 617-724-8769; e-mail: batchelor{at}helix.mgh.harvard.edu

Although survival in patients with malignant gliomas remains limited, there is renewed optimism with the emergence of novel treatment strategies. Cytotoxic agents such as temozolomide and CPT-11 have shown promising clinical activity. Biological treatments for brain tumors, including antisense oligonucleotides, gene therapy, and angiogenesis inhibitors, are also being evaluated in clinical trials. Delivery strategies have been developed to overcome challenges presented by the blood-brain barrier. These noteworthy treatments, alone or in combination, may ultimately prolong survival and enhance quality of life in this group of patients.

Key Words. Glioma • Chemotherapy • Gene therapy • Angiogenesis • Clinical trials • Antisense • Cytokine • Immunotherapy

This article has been cited by other articles:

				V. Garcia-Escudero, R. Gargini, and M. Izquierdo Glioma Regression In vitro and In vivo by a Suicide Combined Treatment Mol. Cancer Res., March 1, 2008; 6(3): 407 - 417. [Abstract] [Full Text] [PDF]

				S. Wu, L. Meng, S. Wang, W. Wang, L. Xi, X. Tian, G. Chen, Y. Wu, J. Zhou, G. Xu, et al. Reversal of the malignant phenotype of cervical cancer CaSki cells through adeno-associated virus-mediated delivery of HPV16 E7 antisense RNA. Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 2032 - 2037. [Abstract] [Full Text] [PDF]

				L. Zilberberg, S. Shinkaruk, O. Lequin, B. Rousseau, M. Hagedorn, F. Costa, D. Caronzolo, M. Balke, X. Canron, O. Convert, et al. Structure and Inhibitory Effects on Angiogenesis and Tumor Development of a New Vascular Endothelial Growth Inhibitor J. Biol. Chem., September 12, 2003; 278(37): 35564 - 35573. [Abstract] [Full Text] [PDF]

				D. B. Bocangel, S. Finkelstein, S. C. Schold, K. K. Bhakat, S. Mitra, and D. M. Kokkinakis Multifaceted Resistance of Gliomas to Temozolomide Clin. Cancer Res., August 1, 2002; 8(8): 2725 - 2734. [Abstract] [Full Text] [PDF]

				G. Auf, A. F. Carpentier, L. Chen, C. Le Clanche, and J.-Y. Delattre Implication of Macrophages in Tumor Rejection Induced by CpG-oligodeoxynucleotides Without Antigen Clin. Cancer Res., November 1, 2001; 7(11): 3540 - 3543. [Abstract] [Full Text] [PDF]

				C. Sanchez, M. L. de Ceballos, T. G. del Pulgar, D. Rueda, C. Corbacho, G. Velasco, I. Galve-Roperh, J. W. Huffman, S. Ramon y Cajal, and M. Guzman Inhibition of Glioma Growth in Vivo by Selective Activation of the CB2 Cannabinoid Receptor Cancer Res., August 1, 2001; 61(15): 5784 - 5789. [Abstract] [Full Text] [PDF]

				D. M. Kokkinakis, R. M. Hoffman, E. P. Frenkel, J. B. Wick, Q. Han, M. Xu, Y. Tan, and S. C. Schold Synergy between Methionine Stress and Chemotherapy in the Treatment of Brain Tumor Xenografts in Athymic Mice Cancer Res., May 1, 2001; 61(10): 4017 - 4023. [Abstract] [Full Text]

				B. A. Teicher, K. Menon, E. Alvarez, E. Galbreath, C. Shih, and M. Faul Antiangiogenic and Antitumor Effects of a Protein Kinase C{beta} Inhibitor in Human T98G Glioblastoma Multiforme Xenografts Clin. Cancer Res., March 1, 2001; 7(3): 634 - 640. [Abstract] [Full Text]

				M. R. Graf, R. M. Prins, and R. E. Merchant IL-6 Secretion by a Rat T9 Glioma Clone Induces a Neutrophil-Dependent Antitumor Response with Resultant Cellular, Antiglioma Immunity J. Immunol., January 1, 2001; 166(1): 121 - 129. [Abstract] [Full Text] [PDF]

				H. S. Friedman, T. Kerby, and H. Calvert Temozolomide and Treatment of Malignant Glioma Clin. Cancer Res., July 1, 2000; 6(7): 2585 - 2597. [Abstract] [Full Text]